T-cell non-Hodgkin lymphoma (Cancer)
Information
- Disease name
- T-cell non-Hodgkin lymphoma
- Disease ID
- DOID:0081312
- Description
- "A non-Hodgkin lymphoma of T-cell lineage." [url:https\://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/t-cell-lymphoma.html]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04774068 | Active, not recruiting | Phase 1 | Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | September 1, 2021 | December 31, 2024 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT00992446 | Completed | Phase 2 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | September 2, 2010 | October 29, 2019 |
| NCT00723099 | Completed | Phase 2 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | June 25, 2008 | July 31, 2018 |
| NCT01919619 | Completed | Phase 2 | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | November 4, 2013 | May 3, 2024 |
| NCT02424968 | Completed | Phase 2 | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma | June 2015 | April 2021 |
| NCT00880815 | Completed | Phase 1 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | February 17, 2009 | May 28, 2019 |
| NCT03061188 | Completed | Phase 1 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | May 23, 2017 | August 4, 2020 |
| NCT03263637 | Completed | Phase 1 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | October 24, 2017 | September 30, 2021 |
| NCT03833180 | Completed | Phase 1 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | March 14, 2019 | December 18, 2023 |
| NCT05377827 | Recruiting | Phase 1 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | October 10, 2023 | April 30, 2026 |
| NCT02859402 | Recruiting | Phase 2 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas | December 2016 | December 2027 |
| NCT03195010 | Terminated | Phase 2 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | June 9, 2017 | December 21, 2018 |
| NCT01746173 | Terminated | Phase 2 | CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma | July 2013 | October 2014 |
| NCT04594135 | Unknown status | Phase 1 | Anti-CD5 CAR T Cells for Relapsed/Refractory T Cell Malignancies | December 1, 2020 | November 30, 2023 |
| NCT04934774 | Unknown status | Phase 1 | Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances | December 1, 2020 | June 1, 2023 |
| NCT05127135 | Unknown status | Phase 1 | Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies | January 22, 2020 | December 24, 2023 |
- Disase is a (Disease Ontology)
- DOID:0060060
- Cross Reference ID (Disease Ontology)
- ICDO:9702/3
- Cross Reference ID (Disease Ontology)
- MESH:D016399
- Cross Reference ID (Disease Ontology)
- NCI:C3466
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:3172003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0079772